Oniria Therapeutics Closes a Financing Round of €1.2 Million

Oniria Therapeutics set to advance cancer research. The biopharmaceutical company has closed a round of financing of €1.2 million led by Mind the Gap of the Botín Foundation, according to the company’s statement.

Oniria Therapeutics was founded in 2021 by Esther Rimbau, current CEO, and Héctor G. Palmer, president of the biopharmaceutical company. The company emerged as a spin-off of the Vall d’Hebron Institute of Oncology (Vhio), the University of Barcelona (UB), and the Catalan Institute for Research and Advanced Studies (Icrea).

The company specializes in the development of a drug to fight persistent tumor cells, which are the ones that cause metastasis and direct patients toward deadly phases. The objective of this round is for the company to advance in the development of a drug to eliminate latent tumor cells in conventional treatments.

In the round, led by the Botín Foundation’s biotechnological entrepreneurship program, BStartups from Banco Sabadell participated, as well as business angels and public injection by Startup Capital de Acció and Investigo de Agaur (both from the Generalitat de Catalunya) Torres Quevedo of the Ministry of Science and Innovation and Investigation.

Read more about Oniria Therapeutics and its latest financing round, and find the most important financial news of the day with the Born2Invest mobile app.

Oniria Therapeutics has conducted preclinical trials with effective results in colon cancer, melanoma, and acute myeloid leukemia in animals

The general director of the Botín Foundation, Íñigo Sáenz de Miera, has pointed out that “the investment in Oniria Therapeutics reinforces our commitment to the transfer of technology to Spanish entrepreneurs who develop therapeutic innovation with a high socio-sanitary impact.”

The company, based at the Cellex Center of the Vall d’Hebron hospital campus in Barcelona, ​​has carried out preclinical studies with different drugs that activate the TET2 enzyme and the results have been effective in animal models of colon cancer, melanoma, and acute myeloid leukemia.

Oniria’s board of directors will be made up of Héctor G. Palmer, who is the scientific director and will hold the position of president, while Esther Riambau and Marc Ramis, business advisors representing the Botín Foundation, will be members.

Rimbau has highlighted that “attacking the latency of cancer cells opens up new treatment avenues that can cure or prolong the lives of millions of patients”, and has pointed out that “the resources of this round will allow us to select our final drug candidate to enter in the regulatory preclinical phase at the beginning of 2024”.

Oniria Therapeutics is a company dedicated to the development of precision drugs in the preclinical stage focused on the elimination of persistent tumor cells, which are responsible for 90% of cancer deaths.

 

__

(Featured image by kkolosov via Pixabay)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.